Pure Global
NCT06356662

Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
The Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Parkinson Disease
Drug/Device/Intervention
Tenofovir Disoproxil Fumarate
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Location
Hangzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Jan 23, 2024
End date
Dec 31, 2024
Enrollment
60 participants
Primary outcome

UPDRS III（Unified Parkinson's Disease Rating Scale part 3）

Summary

To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of
 Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in
 early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take
 Tenofovir disoproxil fumarate at different time points were compared.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismSecondary parkinsonism, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06356662
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06356662 through Pure Global AI's free database. This Phase 1 trial is sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine and is currently Recruiting. The study focuses on Parkinson Disease. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.